Annovis Bio, Inc. Current Liabilities
Annovis Bio, Inc. (ANVS) had Current Liabilities of $6.36 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-14
- 2026-06-30: Liabilities, Current $6.36M.
- 2026-03-31: Liabilities, Current $12.79M.
- 2025-12-31: Liabilities, Current $3.64M.
- 2025-09-30: Liabilities, Current $3.73M.
| Period end | Liabilities, Current | Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $6.36M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $12.79M 10-Q · filed 2026-05-15 | |
| 2025-12-31 | $3.64M 10-Q · filed 2026-08-14 | |
| 2025-09-30 | $3.73M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $2.81M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $2.50M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $3.88M 10-K · filed 2026-03-13 | |
| 2024-09-30 | $5.39M 10-Q · filed 2024-11-08 | |
| 2024-06-30 | $4.06M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $4.87M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $4.28M 10-K · filed 2025-03-21 | |
| 2023-09-30 | $3.56M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $2.07M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $5.41M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $7.70M 10-K · filed 2024-03-29 | |
| 2022-09-30 | $2.53M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $1.30M 10-Q · filed 2023-08-14 | |
| 2022-03-31 | $1.40M 10-Q · filed 2023-05-10 | $1.26M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $1.51M 10-K · filed 2023-03-31 | |
| 2021-09-30 | $1.12M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $884.08K 10-Q · filed 2021-07-28 | |
| 2021-03-31 | $1.60M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $578.38K 10-K · filed 2022-03-02 | |
| 2020-09-30 | $281.06K 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $702.94K 10-Q · filed 2020-07-29 | |
| 2020-03-31 | $749.30K 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $2.01M 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |